Nintedanib y pirfenidona en el tratamiento farmacológico de la fibrosis pulmonar idiopática: Perspectivas actuales y futuras

Translated title of the contribution: Nintedanib and pirfenidone for the treatment of idiopathic pulmonary fibrosis: Current and future perspectives

Javier Leonardo Galindo, Carlos Andrés Celis, Mayra Mejía

Research output: Contribution to journalArticlepeer-review

Abstract

Idiopathic pulmonary fibrosis is a progressive and fatal disease. In recent years, some factors involved in the pathophysiology of the alveolar epithelial injury and in the abnormal remodeling that lead to fibrosis have been identified, some factors involved in the pathophysiology of the alveolar epithelial injury and in the abnormal remodeling that lead to fibrosis have been identified, some of them have been evaluated for the development of specific treatments. Two disease-modifying therapies, pirfenidone and nintedanib, have demonstrated to reduce the progression of the disease, in terms of decline in forced vital capacity, with a borderline effect on mortality. These drugs have been approved for patients with mild to moderate impairment in pulmonary function tests. Real-life studies have evaluated these treatments in populations not represented in clinical trials, with similar benefits, safety and tolerance. Pirfenidone and nintedanib have different safety profiles, but none is better in terms efficacy. Decision to start treatment should weight the severity of the disease and the patient’s expectations and preferences. Combined drug treatment possibly will be the standard of treatment in the future, but further studies must assess its efficacy.

Translated title of the contributionNintedanib and pirfenidone for the treatment of idiopathic pulmonary fibrosis: Current and future perspectives
Original languageSpanish
Pages (from-to)369-385
Number of pages17
JournalInvestigacion Clinica (Venezuela)
Volume59
Issue number4
DOIs
StatePublished - 2018
Externally publishedYes

Fingerprint

Dive into the research topics of 'Nintedanib and pirfenidone for the treatment of idiopathic pulmonary fibrosis: Current and future perspectives'. Together they form a unique fingerprint.

Cite this